- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Meeting and event spending increased in 2000
Pharmaceutical meetings and events continue to grow as integral elements in overall promotion of prescription drugs, according to Newtown, PA-based Scott-Levin's "Physician Meeting & Event Audit," a survey of more than 3,400 doctors. The survey found that pharmaceutical companies spent $1.9 billion on events for physicians in 2000, 14% more than in 1999.
Pharmaceutical meetings and events continue to grow as integral elements in overall promotion of prescription drugs, according to Newtown, PA-based Scott-Levin's "Physician Meeting & Event Audit," a survey of more than 3,400 doctors. The survey found that pharmaceutical companies spent $1.9 billion on events for physicians in 2000, 14% more than in 1999.
By comparison, the industry spent the same amount on direct-to-consumer ads for prescription products between January and September 2000.
The survey also found that pharmaceutical companies devoted an average of 17% of their promotional budgets to meetings and events, about the same proportion as in 1999. Total promotional spending for prescription drugs rose from $9 billion to $10.4 billion in 2000.
Scott-Levin projects that 314,022 physician events were held in 2000, an increase of about 11%. Event activity almost doubled between 1996 and 2000. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
